The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
Under the new framework, Indian tariffs on EU pharmaceutical exports currently at 11 percent and chemicals currently up to 22% will drop to 0 percent for almost all products. Similarly, 90 percent of medical and surgical equipment will see tariffs fall from 27.5 percent to zero.
EU will reciprocate by cutting tariffs on 97.5 percent of India’s chemical exports from 12.8 percent to zero, a move expected to catalyze growth in bulk and specialty chemicals. Indian pharmaceuticals already enjoy zero duty entry into the EU, but the deal would offer preferential access to the EU pharma market and improved competitiveness for medical devices.
The free flow of pharmaceutical, chemicals and machinery will help India to plug into global supply chain and offers Europe an alternative supply base and market..
EU also clarified that all imports from India to the EU will continue to be subject to the EU’s strict health and product safety rules, with no exception.
On the contentious intellectual property (IP) rights, EU said the agreement also provides a high level of protection and enforcement of IP rights, including with respect to copyright, trademarks, designs, protection of trade secrets and undisclosed information, plant varieties.
Reference:
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Sodium Hyaluronate is the sodium salt of hyaluronic acid, a naturally occurring glycosaminoglycan known for its exceptional ability to retain moisture, along with its viscoelastic and biocompatible properties, making it highly valuable across pharmaceutical, cosmetic, and biomedical applications.
Pyrazinamide is a first-line antitubercular drug used in combination therapy for the treatment of tuberculosis (TB). It is a synthetic pyrazine derivative and acts as a prodrug, which is converted into its active form (pyrazinoic acid) inside Mycobacterium tuberculosis.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.